TY - JOUR
T1 - Testosterone and Cardiovascular Disease
AU - Kloner, Robert A.
AU - Carson, Culley
AU - Dobs, Adrian
AU - Kopecky, Stephen
AU - Mohler, Emile R.
N1 - Publisher Copyright:
© 2016 American College of Cardiology Foundation
PY - 2016/2/9
Y1 - 2016/2/9
N2 - Testosterone (T) is the principal male sex hormone. As men age, T levels typically fall. Symptoms of low T include decreased libido, vasomotor instability, and decreased bone mineral density. Other symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass. Epidemiology studies show that low levels of T are associated with more atherosclerosis, coronary artery disease, and cardiovascular events. However, treating hypogonadism in the aging male has resulted in discrepant results in regard to its effect on cardiovascular events. Emerging studies suggest that T may have a future role in treating heart failure, angina, and myocardial ischemia. A large, prospective, long-term study of T replacement, with a primary endpoint of a composite of adverse cardiovascular events including myocardial infarction, stroke, and/or cardiovascular death, is needed. The Food and Drug Administration recently put additional restrictions on T replacement therapy labeling and called for additional studies to determine its cardiac safety.
AB - Testosterone (T) is the principal male sex hormone. As men age, T levels typically fall. Symptoms of low T include decreased libido, vasomotor instability, and decreased bone mineral density. Other symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass. Epidemiology studies show that low levels of T are associated with more atherosclerosis, coronary artery disease, and cardiovascular events. However, treating hypogonadism in the aging male has resulted in discrepant results in regard to its effect on cardiovascular events. Emerging studies suggest that T may have a future role in treating heart failure, angina, and myocardial ischemia. A large, prospective, long-term study of T replacement, with a primary endpoint of a composite of adverse cardiovascular events including myocardial infarction, stroke, and/or cardiovascular death, is needed. The Food and Drug Administration recently put additional restrictions on T replacement therapy labeling and called for additional studies to determine its cardiac safety.
KW - angina
KW - heart failure
KW - hormone replacement therapy
KW - major adverse cardiovascular events
KW - male health
KW - myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=84973449706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973449706&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2015.12.005
DO - 10.1016/j.jacc.2015.12.005
M3 - Review article
C2 - 26846952
AN - SCOPUS:84973449706
SN - 0735-1097
VL - 67
SP - 545
EP - 557
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 5
ER -